Since March 2020, Julia has been the Global Head of IP for Sandoz. In her previous roles with Sandoz, she has had a leading role in the first wave of US biosimilars litigation, including the first litigations on critical aspects of the governing legislation (the Biologics Price Competition and Innovation Act or BPCIA), culminating in the landmark US Supreme Court decision, Sandoz v Amgen.

Since leaving private practice at Corrs Chambers Westgarth, Julia has been in-house counsel for many years including at Mayne Pharma and Hospira Inc before joining Sandoz in 2008. While there, she has taken on roles in European public affairs and led Sandoz’s global IP litigation function as Global Head of IP Litigation. Through those roles, she has maintained a keen interest in IP strategy and litigation worldwide, including cases arising under the Hatch-Waxman and BPCIA legislation in the US, PM(NOC) regulations in Canada and litigation arising from patent linkage systems around the world.